2025年度业绩快报公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 证券代码：688426 证券简称：康为世纪 公告编号：2026-010 江苏康为世纪生物科技股份有限公司 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以江苏康为世纪 生物科技股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：万元 ■ 注：1、本报告期初数同法定披露的上年年末数。 2、除列明以"元"为单位以及加权平均净资产收益率外，本报告期、上年同期所列数据均以"万元"为单 位。 3、以上财务数据及指标以合并报表数据填列，但未经审计，最终结果以公司2025年年度报告为准。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 1、经营情况 2、财务状况 报告期末，公司总资产151,054.23万元，较报告期初下降6.65%；归属于母公司的所有者权益135,524.12 万元，较报告期初下降7.54%。 3、影响 ...

Core Viewpoint - China Biotechnology Services (08037) has successfully completed the issuance of convertible bonds totaling $35 million, with all conditions of the subscription agreement met as of February 20, 2026 [1] Group 1: Convertible Bonds Issuance - The company issued convertible bonds with a principal amount of $35 million, completing the issuance as per the terms of the subscription agreement [1] - Prior to this issuance, there was an outstanding principal amount of $6 million from the 2024 convertible bonds, which can be converted into a total of 39.25 million shares at a conversion price of HKD 1.20 per share [1] - Following the completion of the new convertible bond issuance, the conversion price for the 2024 convertible bonds has been adjusted from HKD 1.20 to HKD 1.11 per share, effective from February 20, 2026 [1] Group 2: Share Issuance and Terms - The maximum number of shares to be issued upon full conversion of the 2024 convertible bonds is 42.432 million shares, effective from the completion date of the new convertible bond issuance [1] - All other terms of the 2024 convertible bonds remain unchanged despite the adjustment in the conversion price [1]

Core Viewpoint - Shanghai Junyile Biotechnology Co., Ltd. has been established with a registered capital of 500 million RMB, fully owned by Shanghai Junshi Biosciences Co., Ltd. [1] Company Information - The legal representative of Shanghai Junyile Biotechnology Co., Ltd. is Xie Wan [1] - The company is registered with a capital of 500 million RMB [1] - The business scope includes technology services, development, consulting, exchange, transfer, promotion, import and export of goods, and information consulting services [1] - The company is classified under the national standard industry of scientific research and technical service industry, specifically technology promotion and application service industry [1] - The registered address is located in the China (Shanghai) Pilot Free Trade Zone Lingang New Area [1] - The company is a limited liability company with no fixed term of operation [1] Shareholding Structure - Shanghai Junshi Biosciences Co., Ltd. holds 100% of the shares in Shanghai Junyile Biotechnology Co., Ltd. [1]

Core Viewpoint - China Biotechnology Services (08037) has entered into a subscription agreement with Fucai Holdings to issue convertible bonds worth $35 million, equivalent to approximately HKD 272.3 million, aimed at strengthening the company's capital base and financial position [1] Group 1: Convertible Bonds Issuance - The company has conditionally agreed to issue convertible bonds with a principal amount of $35 million [1] - The initial conversion price is set at HKD 0.66 per share, which is subject to adjustment [1] - If the conversion rights attached to the bonds are fully exercised, up to 412.6 million shares will be issued, representing approximately 42.28% of the total shares currently in issue [1] Group 2: Impact on Shareholders - The issuance of convertible bonds will not cause immediate dilution of existing shareholders' equity [1] - If the conversion rights are exercised, the total number of shares issued will increase by approximately 29.72%, assuming no changes in the company's issued share capital from the announcement date until conversion [1] Group 3: Investor Profile - The subscriber, Fucai Holdings, primarily engages in investment activities across various sectors, including life sciences, education, internet, technology media, and telecommunications, managing assets exceeding $100 million [1] Group 4: Strategic Rationale - The board believes that the subscription will enhance the company's capital foundation, preparing for long-term development and improving financial conditions [1] - The issuance of convertible bonds is seen as an opportunity to expand and strengthen the capital base while attracting new investors to broaden the shareholder base [1]

Core Viewpoint - China Biotechnology Services (08037.HK) has entered into a subscription agreement with Fucheng Holdings Limited for the issuance of convertible bonds totaling $35 million, equivalent to approximately HKD 272.3 million, with a conversion price set at HKD 0.66 per share, representing a discount of about 16.46% from the closing price of HKD 0.79 on the agreement date [1] Group 1 - The total principal amount of the convertible bonds is $35 million, which will result in a maximum issuance of approximately 413 million shares, accounting for about 42.28% of the total shares outstanding as of the announcement date [1] - The net proceeds from the issuance of the convertible bonds are expected to be approximately $33.9 million [1] - The company plans to allocate 47.6% of the net proceeds for repaying other loans' principal and interest [1] Group 2 - 25.8% of the net proceeds will be used for the development and construction of a network of boron neutron capture therapy centers for cancer treatment [1] - 5.7% of the net proceeds will be allocated for research and development costs [1] - 20.9% of the net proceeds will be utilized for general working capital purposes [1]

Core Insights - Shanghai Muyuan Chunsheng Biotechnology Co., Ltd. has been established with a registered capital of 500,000 RMB [1] - The company is engaged in a variety of services including technology services, health consulting, and management consulting [1] Company Overview - The legal representative of the company is Zhu Rui [1] - The business scope includes technology development, consulting, and transfer, as well as health consulting services excluding medical diagnosis [1] - Additional services offered include information technology consulting, social and economic consulting, engineering management, patient companionship, and sales of cosmetics and daily necessities [1] Business Activities - The company is authorized to conduct business activities autonomously based on its business license, excluding projects that require approval [1] - The company also engages in the wholesale and retail of cosmetics, internet sales (excluding licensed products), and sales of sanitary and disposable medical supplies [1]

Core Points - Recently, Kunming Quanlai Biotechnology Co., Ltd. was established with a registered capital of 1 million RMB [1] - The legal representative of the company is Lin Shangjun [1] - The business scope includes licensed projects such as beauty services, medical beauty services, and fertilizer production [1] Business Scope - Licensed Projects: - Life beauty services - Medical beauty services - Fertilizer production [1] - General Projects: - Technical services, development, consulting, exchange, transfer, and promotion - Fertilizer sales - Research and development of biological organic fertilizers - Chemical fertilizer sales - Mixed processing of soil and fertilizers - Nail services - Import and export of goods - Import and export of technology - Import and export agency - Wholesale of computer software, hardware, and auxiliary equipment - Information system integration services [1]

Financial Data and Key Metrics Changes - Q3 2025 revenue was $104.6 million, reflecting a 10% year-over-year growth [4][14] - Adjusted EBITDA for Q3 was $35.2 million, with a margin of 34% [4][18] - Q3 bookings totaled $96.6 million, representing a 1% increase year-over-year [5][14] - The company narrowed its revenue guidance for 2025 to $415-$420 million, indicating 8%-9% growth compared to 2024 [5][20] Business Line Data and Key Metrics Changes - Software revenue reached $43.8 million, growing 22% year-over-year, with organic growth of 6% [10][15] - Service revenue was $60.8 million, up 3% year-over-year, driven by growth in QSP services [11][17] - Software bookings of $40.8 million increased 17%, while service bookings declined 9% [10][17] Market Data and Key Metrics Changes - Tier 1 services customers exhibited cautious spending behavior, impacting deal timelines [5][6] - The adoption of biosimulation solutions is increasing among large pharma customers, particularly in model-informed drug development [6][8] Company Strategy and Development Direction - The company is focused on investing in R&D and commercial teams, with R&D spending up 24% year-over-year [4][11] - Certara is expanding its software capabilities into discovery and preclinical phases, enhancing its product offerings [9][30] - The strategic review of the regulatory services business is nearing completion, with a definitive outcome expected by the end of 2025 [12] Management's Comments on Operating Environment and Future Outlook - Management noted a slowdown in deal completion timelines, particularly in regulatory services, due to large pharma customers adjusting their R&D focus [6][12] - There are positive leading indicators for the biosimulation market, with expectations for continued growth in 2026 [6][20] - Management expressed cautious optimism regarding macroeconomic stability and its potential positive impact on customer spending [35][46] Other Important Information - The company completed the Chemaxon acquisition, which has contributed positively to revenue and is expected to reach corporate average margins by year-end [9][19] - The company has repurchased approximately $41 million of stock as part of a $100 million share repurchase program [19] Q&A Session Summary Question: What is the dynamic regarding tier one services revenue or bookings? - Management noted delays in decision-making among tier one customers, with expectations for some deals to close in Q4 and others pushed to 2026 [23][24] Question: Can you comment on the gross profit outperformance? - Management attributed gross margin improvement to productivity gains and a favorable mix shift towards software [25][26] Question: How is the growth of QSP expected to evolve? - The company aims to standardize QSP modeling through its new software platform, Certara IQ, which is expected to drive efficiency and financial benefits [27][30] Question: What is the outlook for tier two and tier three services? - Tier two and tier three services have shown good growth, partially offsetting the headwinds faced by tier one services [64][65] Question: How does the company view the impact of AI on its business? - Management sees AI as a significant opportunity, with increased willingness among customers to adopt AI-enabled products [41][42]

Group 1 - The core point of the news is that Aopumai's stock price has decreased by 5.02%, currently trading at 55.87 CNY per share, with a total market capitalization of 6.359 billion CNY [1] - Aopumai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company specializes in cell culture products and services, with product revenue accounting for 87.34% and service revenue for 12.53% [1] Group 2 - From the perspective of major fund holdings, Guotai Fund has a significant position in Aopumai, with its Guotai National Policy Driven Flexible Allocation Mixed A Fund holding 3,140 shares, representing 0.65% of the fund's net value [2] - The Guotai National Policy Driven Flexible Allocation Mixed A Fund has a total scale of 21.707 million CNY and has achieved a year-to-date return of 3.97% [2] - The fund manager, Deng Shifeng, has a tenure of 17 years and has achieved the best fund return of 167.36% during his management period [2]

Meeting Overview - The fourth board meeting of Shanghai Univi Technology Co., Ltd. was held on September 28, 2025, with all nine directors present [2][4]. - The meeting was chaired by Chairman Leng Zhaowu, and it complied with legal and regulatory requirements [2]. Resolutions Passed - The board approved the reappointment of Lixin Zhonglian Certified Public Accountants as the auditing firm for the fiscal year 2025, with a one-year term [3][5]. - The voting results for this resolution were 9 votes in favor, 0 against, and 0 abstentions [4]. Amendments to Company Regulations - The board approved amendments to the company's articles of association and related rules to align with new regulations from the China Securities Regulatory Commission [6][8]. - The voting results for this resolution were also 9 votes in favor, 0 against, and 0 abstentions [7]. Institutional Revisions - The board reviewed and approved multiple revisions to internal governance documents, including the management of fundraising, independent director work, and related party transactions [9][10]. - Each of these revisions received unanimous support with 9 votes in favor, 0 against, and 0 abstentions [11]. Upcoming Shareholder Meeting - The board agreed to convene the third extraordinary general meeting of shareholders on October 16, 2025, combining on-site and online voting methods [22][23]. - The meeting will address the resolutions passed in the board meeting and will require a two-thirds majority for special resolutions [54].